What Axios International does

Axios International is a privately held, Irish-domiciled (Axios International Consultants Ltd) healthcare access solutions provider that designs, manages, and operates patient access and support programs for pharmaceutical clients, healthcare providers, and patients. The company has been operating for approximately 25 years (founded around 1999; firmographic listing cites 1997) and currently runs 240+ active programs across 40+ countries. Its customers span pharmaceutical companies (primary), healthcare providers and physicians, healthcare systems and government ministries, pharmacists, and patients with chronic and rare diseases, with named engagements including the Ministry of Health Malaysia and the National Cancer Society Malaysia.

The company operates a dual-platform architecture. Axios Access Solutions comprises service-based modules — Access Strategy Consulting, Access to Diagnosis, Access to Treatment Solutions, Access to Maximized Adherence, and Remote Care — supported by proprietary tools (PFET for patient financial eligibility, PNAT for patient-needs assessment, Affordability and Economic Modeling, Access Prioritization Tool, and Willingness to Pay and Prescribe Studies). Axios+ is a digital health ecosystem of role-specific applications: MyPatients for physicians, MyHealth for patients, MyPharmacy for pharmacists, MyPrograms for pharmaceutical sponsors, and MyCharity for charitable partners. The newest addition is the On-Time Access (OTA) model, launched in 2024, which addresses cash-flow barriers that delay initiation of specialty medications.

Revenue is generated through three streams: patient access program management (managed services), access strategy consulting (professional services), and digital health platforms under Axios+ (subscription / recurring). Pricing is not publicly disclosed; the go-to-market is direct enterprise sales targeting pharmaceutical companies and healthcare organizations, with no distribution through third-party resellers. The company is founder-led, with Joseph Saba, MD serving as CEO and co-founder, and is governed under Irish law with no parent entity, no disclosed institutional investors, no funding rounds, and no M&A history in the available records.

Name

Axios International

Legal name

Axios International Consultants Ltd

Website

https://axiosint.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Axios International is a privately held, Irish-headquartered healthcare access solutions provider that designs and operates patient access and support programs for pharmaceutical companies, providers, and patients across 40+ countries. It combines managed services, consulting, proprietary tools, and the Axios+ digital health platform spanning physicians, patients, pharmacists, pharma sponsors, and charities.

Ownership category

akta.pro rank

Product category

Healthcare Access Solutions

NAICS

Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Patient Access Programs & Affordability (Copay/Hubs/PSP) (HLAIAKAG)

akta.pro secondary industries

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Specialty Pharmacy–Integrated Telehealth (biologics, complex therapies, REMS) (HLALAIAF), Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG)

Keywords

• Patient access programs
• Healthcare access consulting
• Medication adherence solutions
• Pharmaceutical access strategy
• Patient support services

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Patient Access Program Management: Axios designs and manages patient access and support programs for pharmaceutical companies, helping patients access treatments through programs that address financial barriers, adherence support, and treatment initiation
2. Access Strategy Consulting: Consulting services to help pharmaceutical companies develop access strategies for their products in various markets, including pricing, reimbursement, and distribution strategies
3. Digital Health Solutions: SaaS platforms and digital tools (MyPatients, MyHealth, MyPharmacy, MyPrograms, MyCharity) provided to healthcare providers, patients, pharmacists, and pharmaceutical companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Axios International designs and manages patient access and support programs on behalf of pharmaceutical companies, helping patients overcome financial, diagnostic, and adherence barriers to specialty medications. Its offerings span access strategy consulting, diagnosis access, treatment access, adherence maximization, and remote care services, enabled by proprietary tools (PFET, PNAT, Affordability Modeling, Access Prioritization) and the Axios+ digital health ecosystem of physician, patient, pharmacist, pharma, and charity applications.

Product overview

Axios International operates a dual-platform architecture consisting of Axios Access Solutions (consulting and service-based access programs) and Axios+ (digital health ecosystem). Axios Access Solutions provides a comprehensive suite including strategy consulting, access to diagnosis, treatment access, adherence maximization, and remote care solutions, supported by tools like PFET, PNAT, and Affordability Modeling. Axios+ is a digital health platform comprising five applications: MyPatients (physician app), MyHealth (patient app), MyPharmacy (pharmacist app), MyPrograms (pharma company web app), and MyCharity (charity portal). The company also introduced the On-Time Access (OTA) model as an innovative approach to overcome patient access barriers.

Differentiator

Problem solved

Functional benefit

Brands

• MyPatients: App for physicians to manage patient care
• MyHealth
• MyPharmacy
• MyPrograms
• MyCharity

Products and services

• Axios Access Solutions End-to-end suite of healthcare access services for pharmaceutical companies covering strategy consulting, patient diagnosis access, treatment access, adherence maximization, and remote care, designed to improve patient outcomes and healthcare system sustainability.
• Access Strategy Consulting Consulting service helping pharmaceutical companies develop market access strategies, including affordability modeling, willingness-to-pay studies, and access prioritization analyses.
• Access to Diagnosis Solutions focused on improving patient access to diagnostic services and testing, supporting earlier identification of conditions that require specialty treatment.
• Access to Treatment Solutions Programs that help patients overcome financial and administrative barriers to accessing specialty medications, including the On-Time Access (OTA) model for addressing cash-flow constraints that delay treatment initiation.
• Access to Maximized Adherence Services designed to improve patient treatment adherence through personalized interventions, supported by the PNAT assessment tool, aimed at chronic and long-term therapies.
• Remote Care Solutions Digital health services providing remote healthcare delivery, monitoring, and patient support capabilities that supplement traditional in-person care.
• Axios+ Digital Health Platform Digital health ecosystem providing patient, physician, pharmacist, pharmaceutical, and charity-facing applications that operationalize and manage patient access and support programs.
• On-Time Access (OTA) Model Innovative access model designed to overcome financial and administrative barriers to specialty medications by addressing cash-flow challenges that delay treatment initiation.

Quantifiable outcome

• Adherence to long-term therapy for chronic illnesses averages 50% in developed countries, with even lower rates in low- and middle-income countries - Axios aims to improve these rates through personalized adherence interventions

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

One partnership is on record.

• Dar Al Ber SocietycoreStrategic or Co-development PartnerPartnership to announce an access-focused pharmacy initiative, combining Axios' expertise in patient access solutions with Dar Al Ber Society's charitable healthcare mission to improve medication accessibility

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Veeva Systems: Provider of cloud-based software for the pharma industry, including patient and commercial platforms. Veeva's expanding software stack overlaps with Axios+' MyPrograms-style pharma program management capabilities and could compete for digital tooling spend.
• Decision Resources Group (DRG, part of Clarivate): Provides market access insights, pricing data, and analytics for pharma companies, overlapping with Axios' Willingness to Pay/Prescribe studies, access prioritization, and affordability modeling tools.

Direct peers

• Eversana: Commercial services firm providing patient access, hub, adherence, and market access services to pharmaceutical manufacturers. Direct overlap with Axios' patient support program management and access-to-treatment offerings.
• ZS Associates: Management consulting firm with deep pharma specialization, particularly in market access, pricing, and patient access strategy. Competes with Axios on access strategy consulting engagements and serves many of the same pharmaceutical clients with overlapping offerings.
• Charles River Associates (CRA): Life sciences practice that advises pharmaceutical and biotech clients on market access, pricing, and commercial strategy, overlapping directly with Axios' access strategy consulting engagements.
• Trinity Life Sciences: Specialized pharma consulting firm offering market access, commercial strategy, and patient services insights that overlap with Axios' consulting and willingness-to-pay/adherence offerings for pharma clients.
• AmerisourceBergen (Lash Group / PharmaLex): Through its Lash Group and PharmaLex units, AmerisourceBergen offers patient access, hub, and patient support program services that directly overlap with Axios' core PSP and adherence offerings to pharma manufacturers.

Broad incumbents

• Parexel International: Large CRO and pharma services provider with patient access and commercial services capabilities. While broader in scope, Parexel competes with Axios on access strategy and patient program engagements for biopharma sponsors.
• IQVIA: Global leader in healthcare data, analytics, and pharma services with a substantial market access and patient services practice. Directly competes with Axios in access strategy consulting and patient support programs for pharmaceutical clients, but operates at much greater scale across a broader service portfolio.
• McKinsey & Company (Pharma Practice): Global management consulting firm whose pharma practice covers market access, pricing, and patient services strategy. Competes with Axios' Access Strategy Consulting offering on the most strategic access engagements with large pharma clients.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Axiosint
• Facebookfacebook.com/axiosint

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axios International